MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Type
Public
HQ
South San Francisco, US
Size (employees)
102 (est)+5%
MyoKardia is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at MyoKardia

Tassos Gianakakos

Tassos Gianakakos

Chief Executive Officer
Robert McDowell

Robert McDowell

Chief Scientific Officer
June Lee

June Lee

Chief Operating Officer and Chief Development Officer
Marc Semigran

Marc Semigran

Chief Medical Officer
Jake Bauer

Jake Bauer

Chief Business Officer
Taylor Harris

Taylor Harris

Chief Financial Officer
Show more

MyoKardia Office Locations

MyoKardia has an office in South San Francisco
South San Francisco, US (HQ)
333 Allerton Ave
Show all (1)
Report incorrect company information

MyoKardia Financials and Metrics

MyoKardia Financials

MyoKardia's revenue was reported to be $39.20 m in FY, 2016 which is a 176.1% increase from the previous period.
USD

Net income (Q1, 2018)

(17.8 m)

EBIT (Q1, 2018)

(18.6 m)

Market capitalization (15-May-2018)

1.7 b

Closing share price (15-May-2018)

47

Cash (31-Mar-2018)

183.9 m
MyoKardia's current market capitalization is $1.7 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

14.2 m39.2 m

Revenue growth, %

176%

General and administrative expense

9 m16.3 m22 m

R&D expense

28.4 m36.2 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

3.6 m3.5 m3.6 m5.6 m5.6 m5.6 m

General and administrative expense

3.9 m4.1 m4 m5.5 m5.1 m5.9 m7.3 m

R&D expense

8.1 m9.3 m8.8 m11.9 m13.7 m14.4 m16.6 m

Operating expense total

12 m13.3 m12.8 m17.4 m18.8 m20.2 m23.9 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

112.3 m135.8 m224.6 m

Accounts Receivable

45 m

Prepaid Expenses

1.3 m1.4 m

Current Assets

113.5 m186.3 m259.4 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

99.5 m87.6 m77.1 m135.6 m117.3 m227.2 m183.9 m

Prepaid Expenses

1.2 m1.1 m762 k1.8 m1.2 m1.5 m

Current Assets

100.7 m88.7 m77.9 m149.4 m134.6 m248.7 m226 m

PP&E

3 m2.9 m2.7 m2.6 m2.9 m2.6 m4 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(22.9 m)(13.2 m)(46 m)

Depreciation and Amortization

965 k1.1 m1.3 m

Accounts Payable

1.3 m(434 k)367 k

Cash From Operating Activities

(32.1 m)(20.9 m)(9.8 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(8.4 m)(18.2 m)(27.4 m)(11.5 m)(24.4 m)(38.6 m)(17.8 m)

Depreciation and Amortization

256 k531 k815 k316 k634 k977 k300 k

Accounts Payable

(115 k)(436 k)(372 k)629 k(488 k)228 k212 k

Cash From Operating Activities

(12.1 m)(23.9 m)(34.4 m)28 m(13.8 m)(3.2 m)(16.6 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

MyoKardia Operating Metrics

FY, 2015FY, 2016Mar, 2018

Patents (US)

2 3

Patents Pending (US)

7 7

Patents Pending (foreign)

34 30

Patents Issued

4
Show all operating metrics
Report incorrect company information

MyoKardia News and Updates

Report incorrect company information